Radiopharm Theranostics Receives Approval for Lu-RAD202 Clinical Trials

2 min read | December 20, 2024 12:00 AM AEDT | By Team Kalkine Media

Google News:

Radiopharm Theranostics Receives Approval for Lu-RAD202 Clinical Trials — Image source: shutterstock

Recent News

Could ASX Growth Stocks Be Set for the Next Market Shift?

Woolworths Climbs While Coles Skirts 52-Week Lows: The Supermarket Spl...

Retail Under Pressure: Why ASX Retail Stocks Face a Tougher Road Ahead

ASX Growth Stocks: Hidden Catalysts and Market Signals

Make Kalkine Media
My Trusted Source

Highlights

Radiopharm Theranostics Ltd (ASX:RAD) has gained ethics approval to commence Phase 1 trials for Lu-RAD202, a candidate treatment for HER2-positive breast and gastric cancers.

The trial will assess the safety and initial clinical activity of 177Lu-labelled RAD 202, targeting HER2-expressing solid tumors.

Recruitment for the open-label, dose-escalation trial is set to begin across Australia, marking a significant step toward advancing treatment for patients with unmet medical needs.

Radiopharm Theranostics Ltd (ASX:RAD) has achieved ethics approval from the Belberry Human Research Ethics Committee (HREC) to initiate its Phase 1 clinical trial for Lu-RAD202. This development marks a pivotal milestone in the company’s journey toward providing innovative therapeutic solutions for HER2-positive cancers.

The Phase 1 trial is designed to evaluate both the safety and initial clinical activity of 177Lu-labelled RAD 202 in treating solid tumors that express the human epidermal growth factor receptor 2 (HER2). HER2 is a transmembrane tyrosine kinase receptor associated with tumor growth and survival and is frequently overexpressed in cancers such as breast, gastric, pancreatic, bladder, and gynecological tumors.

Details of the Lu-RAD202 Candidate

Lu-RAD202, a single-domain monoclonal antibody (sdAb), specifically targets HER2. The candidate aims to address a critical treatment gap for HER2-positive metastatic cancer patients who are either refractory to or unable to tolerate existing therapies.

The trial is an open-label, dose-escalation study, and recruitment will be conducted across multiple sites in Australia. This approach is expected to provide valuable data on dosage parameters and the candidate's potential effectiveness.

CEO Commentary on the Trial’s Significance

Radiopharm Theranostics’ CEO and managing director, Riccardo Canevari, expressed confidence in the program's progress. Canevari highlighted the potential of RAD 202 to deliver improved clinical outcomes for patients with advanced HER2-positive cancers while potentially preserving their quality of life.

The initiation of this trial represents an essential step forward in addressing the unmet needs of patients with HER2-positive tumors. Radiopharm Theranostics continues to make strides in advancing its pipeline of innovative treatments, aiming to redefine therapeutic standards in oncology.

Bottomline

The ethics approval for Lu-RAD202's Phase 1 trial underscores the progress Radiopharm Theranostics Ltd is making in the development of cutting-edge oncology treatments. As recruitment begins in Australia, the trial will provide critical insights into the potential of Lu-RAD202 to transform outcomes for patients with HER2-positive metastatic cancers.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.